November 12, 2004 1/3 No: SN. 036/2017 May 11, 2017 Subject: Clarification of Operating Results and Financial Status the six-month period ended March 31, 2017 Attention: President The Stock Exchange
consequently brought the decrease in net profit around 89.84 million baht or 17.49% comparing to last year. Financial Status As of June 30th, 2017, the Company had total assets at 4 ,631.76 million baht, rose by
as follow; Operating performance : 1. Revenue : The total revenue of the year 2018 was Baht 4,151.37 million representing a decrease 7.35% comparing to the total revenue of Baht 4,480.60 million of
Operating Fee for trade mark in China and the change on accounting record of the audit fee expense etc. Finance Cost Q1/2019, the Company and its subsidiaries had the financial cost 1.1 MB decreased by 1.8
31, 2019. The conclusions are as follow; Operating performance : 1. Revenue : The total revenue of the 1st quarter of year 2019 was Baht 705.89 million representing a decrease 45.04% comparing to the
/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
Microsoft Word - Oishi MDA - Year End 2018_EN_v2_Sud.docx Ref. SorNor. 040/2018 November 20, 2018 Subject: Clarification of Operating Results and Financial Status for the year 2018, ended September
operating result for the 1st quarter 2020, revenue from sales decrease from the same period of last year at 5.5%. Gross profit margin is equal to 49.6%. Net profit for the 3-month period ended 31 March 2020
Subject: Clarification for the year Ended May 31, 2019 operating results that posted a difference greater than 20% To: Director and Manager the Stocks Exchange of Thailand World corporation public company
Ref. APURE 024/2023 August 15, 2023 Subject : Financial Position and Operating Performance of year 2022 (Revise) Attention : The Director and President of the Stock Exchange of Thailand Financial